More than 5 billion antifungal drugs Shenyang Xingqi eye drug Volikangaodin eye drops clinical application was accepted.

Pharmaceutical Network June 23- June 20, Shenyang Xingqi eye medicine with the new drug class 2.2 declared the clinical application of Vulcan audor eye drops received by CDE, acceptance number CXHL2000294According to Minnet.com, in 2019 China's public medical institutions terminal Volikangayu sales of 5.369 billion yuan, there is no eye drops on the market sales.Volicazole belongs to a broad-spectrum triamcinols antifungal drug, can inhibit the biosynthesis of fungus margotols, can have bactericidal effect on candidion, courcine and other fungi, is a first-line drug to treat serious cyclic mold infection.Figure 1: Sales of Volikanga, china's public medical institutions terminals (units: 10,000 yuan), show that in recent years, the sales of volikanga in China's urban publichospitals
, county-level public hospitals, urban community centers and township health centers (china's public medical institutions) increased year by year, and in 2019 sales revenue of 5.369 billion yuan, up 4.32% YoY.Figure 2: In 2019, china's public medical institutions terminal Volikangazole dosage patternin 2019 China's public medical institutions terminal Vulcanazola dosage pattern, the highest proportion of injections, up to 55.59 percent, followed by tablets, accounting for 37.43 percent, including ordinary tablets and dispersed tablets.Minet data show that many pharmaceutical companies are developing new dosage forms of Voliconazole, including dry suspension, granules, eye drops and so onOn June 20, Shenyang Xingqi Eye Medicine to the new drug 2.2 class declared the clinical application of Volikangaoodi eye drops to be accepted by CDE, acceptance number CXHL2000294, Shenyang Xingqi eye medicine for the first layout of Volikangao oozing eye dropsenterprise.Source: Minnet database, CDE official websiteNote: data statistics as of June 22, if there are omissions, welcome to point!.